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Summary
Diffuse parenchymal lung disease (DPLD) is a group of diseases that have the common 
characteristic of involving the pulmonary parenchyma diffusely. The pulmonary parenchyma 
consists of all structures distal to the terminal bronchiole. DPLD are numerous, there are some 
150 different entities that qualify for the group. Most of these diseases are diagnosed according 
to common algorithm, but the etiology, prognosis and therapy are quite different. Lung tran-
splantation is the ultimate therapeutic option for some of these diseases, most frequently it is the 
idiopathic pulmonary fibrosis (IPF).
Keywords: diffuse parenchymal lung disease; lung transplantation; idiopathic pulmonary 
fibrosis.
INTRODUCTION
Diffuse parenchymal lung disease (DPLD) comprises a number of clinical dis-
orders [1] that affect the alveoli, alveolar septa, respiratory bronchioli, blood vessels, 
lymph vessels, i.e. the pulmonary parenchyma. These disorders are caused by nu-
merous known agents, may be idiopathic, granulomatous or rare (Table 1).
The known causes are diverse inorganic agents leading to pneumoconioses (asbe-
stos, silica, etc.), organic, causing hypersensitivity pneumonitis (farmer’s lung, bird 
fancier’s lung, etc.), drugs, irradiation, toxic gases and fumes, bacteria, fungi, viru-
ses, protozoa, and parasitic infections or infestations. When treating a patient with 
DPLD the clinician must carry out a detailed occupational and environmental hi-
story [2] because organic dusts are an increasing cause of occupational exposure 
and respiratory disease, pneumoconiosis still accounts for a significant proportion 
of ILDs, new sources of exposure and newly identified agents are emerging and fi-
nally more knowledge regarding the toxicological effects of nanoparticles is funda-
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mental. The exposure to illicit drugs and personal habits should be considered. The 
results of recognition of the offending agent result in its avoidance and prevention. 
For a DPLD to be considered idiopathic all the possible etiologic factors, including 
environmental or occupational, have to be excluded. 
Table 1. Classification of Diffuse Parenchymal Lung Disease (DPLD)
DPLD OF KNOWN CAUSE
• Anorganic particles -pneumoconiosis






IDIOPATHIC INTERSTITIAL PNEUMONIAS 
• Idiopathic pulmonary fibrosis (IPF),
• Non-specific interstitial pneumonia (NSIP),
• Organizing pneumonia (OP), 
• Acute interstitial pneumonia (AIP),
• Desquamative interstitial pneumonia (DIP)
• Respiratory bronchiolitis-interstitial lung disease (RB-ILD), 
• Lymphoid interstitial pneumonia (LIP)
• Pleuropulmonary fibroelastosis (PPFE)
GRANULOMATOSIS
• Sarcoidosis
• Granulomatosis with polyangitis (Wegener’s granulomatosis,)
• Churg-Strauss Syndrome
• Necrotizing sarcoid granuloma
• Lymphomatoid granulomatosis
• Bronchocentric granulomatosis








• Idiopathic pulmonary hemosiderosis 
• Pulmonary manifestation of connective tissue diseases 
37
Rad 522. Medical Sciences, 41(2015) : 35-45
T. Peroš-Golubičić: Diffuse parenchymal lung disease
Idiopathic interstitial pneumonias according to new classification [3] (Table 2) com-
prise of several entities, among them there is a new entity called pleuropulmonary 
fibroelastosis. Also, of great help to the practicing physicians is the inclusion of a 
category of unclassifiable group of DPLD. The everyday life experience resulted in 
this change, because almost 30% of these diseases even after the most complete and 
thorough examination, stay unclassifiable.
The third group consists of diseases that histologically show the pattern of gra-
nuloma, like sarcoidosis.
And finally, the fourth group consists of diverse, mostly rare diseases among 
them diffuse connective tissue diseases (systemic lupus erythematosus, rheuma-
toid arthritis, systemic sclerosis, ankylosing spondylitis, mixed connective tissue), 
lymphangioleiomyomatosis, alveolar proteinosis and alveolar microlythiasis. Some 
of these diseases are benign and self-limiting; others are chronic, progressive, irre-
versible, and fatal. The lung manifestation may be the one manifestation of a syste-
mic process. Or it may be the only organ affected. All DPLDs, however, have certain 
common clinical, imaging, and physiologic features that should be recognized.
Table 2. Revised ATS/ERS classification of idiopathic interstitial pneumonias (IIPs)3
MAJOR IIPs
• Idiopathic pulmonary fibrosis
• Idiopathic non-specific interstitial pneumonia
• Respiratory bronchiolitis–interstitial lung disease
• Desquamative interstitial pneumonia
• Cryptogenic organizing pneumonia
• Acute interstitial pneumonia
RARE IIPs
• Idiopathic lymphoid interstitial pneumonia
• Idiopathic pleuroparenchymal fibroelastosis
UNCLASSIFIABLE IIPs*
*Causes of unclassifiable idiopathic interstitial pneumonia include (1) inadequate clinical, 
radiologic, or pathologic data and (2) major discordance between clinical, radiologic, and 
pathologic findings that may occur in the following situations:(a) previous therapy resulting in 
substantial alteration of radiologic or histologic findings (e.g., biopsy of desquamative interstitial 
pneumonia after steroid therapy, which shows only residual nonspecific interstitial pneumonia 
[153]);(b) new entity, or unusual variant of recognized entity, not adequately characterized by 
the current American Thoracic Society/European Respiratory Society classification(e.g., variant 
of organizing pneumonia with supervening fibrosis) (79); and(c) multiple high-resolution 
computed tomography and/or pathologic patterns that may be encountered in patients with 
idiopathic interstitial pneumonia.
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COMMON CLINICAL FEATURES 
A thorough occupational, history of recent or past exposure to inorganic or mi-
neral particles, or to organic dusts and animal antigens (pets) should be identified. 
Drugs and chemicals known to cause ILD, history of pulmonary infections (particu-
larly HIV), immune disorders, and collagen vascular disorders should be inquired. 
A smoking history, the country of origin and recent travel history are often critical 
for establishing the diagnosis. 
Dyspnea is the most frequent symptom of DPLD. At first, dyspnea is evident 
on exercise; later it progresses to breathlessness at rest. The duration of progressive 
dyspnea usually ranged from months to years. Dyspnea is commonly associated 
with dry cough, particularly on exertion, and fatigue is frequently present. Fever, 
chills, and weight loss are the main symptoms in interstitial pulmonary infections 
but may also occur in collagen vascular disorders. 
In 10% to 15% of the patients who have DPLD, tachypnea is present. Auscultati-
on of the lungs reveals end-inspiratory bibasilar “Velcro®-like” crackles. Wheezing 
is present in 20% of the patients with hypersensitivity pneumonitis as well as the 
squawk, the ominous auscultatory sign, typical for advanced HP. Digital clubbing is 
common in idiopathic pulmonary fibrosis (IPF) and asbestosis.
The most helpful diagnostic procedures are radiographic imaging, chest X- ray and 
high resolution computed tomography (HRCT), bronchoscopy with bronchoalveo-
lar lavage and transbronchial lung biopsy, lung function tests and finally the open 
lung biopsy.
Chest roentgenogram is abnormal in more than 90% of the patients who have 
DPlD. 
High-resolution computed tomography (HRCT) [4] is superior to conventional radio-
graphy in delineating the presence and extent of parenchymal involvement in DPLD. 
HRCT is also useful in characterization of the pattern of the disease, narrowing the 
differential diagnosis, as a guide to the site of biopsy and as an aid in the follow up 
of the patients. 
As a result of inflammation and fibrosis of the alveolar and the vicinal structu-
res, the lung become stiff and have low lung compliance. Lung volumes are reduced, 
diffusing capacity is impaired, and alveolar-to-arterial oxygen difference is widened 
either at rest or exercise or both. The large airway function usually remains normal, 
but the small airway dysfunction is often present. Airway obstruction is prominent 
in some interstitial lung disorders. The exercise testing in everyday management of 
DPlD is very useful.
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Laboratory and immunologic tests are of limited value in establishing the cause of ILD. 
lung biopsy should be performed in diffuse parenchymal lung disease. One sho-
uld attempt to obtain a lung biopsy early in the course of the disease, particularly 
in a young and middle-aged patient. Transbronchial biopsy is useful in the dia-
gnosis of sarcoidosis, alveolar proteinosis, miliary tuberculosis, and Pneumocystis 
pneumonia. The procedure has limitations because the amount of tissue obtained 
is often insufficient for extensive diagnostic studies. Surgical open lung biopsy is 
being replaced by video assisted thoracoscopic (VAT) lung biopsy. The diagnostic 
accuracy of thoracoscopic lung biopsy is equivalent to open lung biopsy. Further-
more, peri-operative morbidity, length of hospital stay, and duration of chest pain 
are significantly lower in patients who undergo thoracoscopic lung biopsy. Recently, 
it has been reported that the awake VATS lung biopsy is easily feasible by regional 
anesthesia and resulted in low morbidity, excellent diagnostic yield, short hospital 
stay, and low cost [5].
Bronchoalveolar lavage (BAL) [6] has expanded our understanding of the patho-
genesis of many interstitial lung diseases. The minimally invasive bronchoalveolar 
lavage (BAL) procedure is an important diagnostic instrument that can facilitate the 
diagnosis of various diffuse parenchymal lung diseases (DPLD). BAL fluid white 
blood cell profiles are analyzed, malignant cells looked for, and in certain circum-
stances particular stains are performed to detect yet other cell types. Additionally, 
BAL can play a very important role in the diagnosis of respiratory tract infections. 
All these analyses are usually readily performed in a moderately equipped cytolo-
gical laboratory.
In the differential diagnosis of diffuse parenchymal lung disorders, sarcoidosis, 
pulmonary affection of connective tissue diseases, idiopathic pulmonary fibrosis, 
and organizing pneumonia are the most common and are responsible for about two 
thirds of all cases [7]. 
MANAGEMENT
The management of diffuse parenchymal lung disease depends upon the pre-
cise diagnosis, and disease extent, activity and severity. Exclusion of exposition, 
etiologic therapy with antibiotics, antifungal agents or antituberculosis drugs, im-
munosuppressants (corticosteroids, azathioprine, cyclophosphamide, methotrexate, 
leflunomide), biologicals and immunomodulators (imfliximab, interferons, rituxi-
mab, nintedanib), antifibrotics (pirfenidon, thalidomide, penicilamin) are all the 
agent of choice in specific circumstances. Symptomatic therapy (oxygen, antitusics) 
is used in advanced cases.
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Pulmonary rehabilitation is also important. The aim of pulmonary rehabilita-
tion is not only to improve daily functioning but also to help people with DPLD 
live full, satisfying lives. To that end, pulmonary rehabilitation programs focus on 
physical exercise, to improve the endurance, breathing techniques that improve 
lung efficiency, emotional support and nutritional counseling
Lung transplantation (LTx) offers a survival benefit in carefully selected patients 
with DPLD. Indications for lung transplant referral among fibrotic lung disease [8] 
are histologic or radiographic evidence of usual interstitial lung disease (UIP) or 
nonspecific interstitial pneumonia (NSIP), FVC<60% predicted, diffusion capacity 
<39% of predicted (UIP) or <35% of predicted (NSIP), drop in FVC by ≥10% or di-
ffusion capacity by ≥15% over 6-month period, drop in SaO2 on pulse oxymetrya 
by <88% on 6-minute walk test, high-resolution CT imaging with honeycombing 
(fibrous score>2), and pulmonary hypertension.
DPLD most frequently subjected to lung transplantation are the diseases [9] 
with UIP like HRCT/PHD pattern (~ 80 % of all LTx for DPLD) like idiopathic pul-
monary fibrosis (IPF), chronic hypersensitivity pneumonits (HP), connective tissue 
disease (CTD) and miscellanea („lung fibroses”, unclassifiable DPLD, etc.). Diseases 
with NSIP like HRCT/PHD pattern (~ 4 % 0f all LTx ), sarcoidosis (~2.5 of all LTx) 
and rare disease: langerhans cell histiocytosis (lCH), microlithiasis, lymohangio-
leiomyomatosis (LAM), pulmonary alveolar proteinosis (PAP) and others, are less 
frequent thus less frequently subjected to LTx.
Idiopathic pulmonary fibrosis comprises some 23% of all the indications for 
lung transplantation, raising its proportion in that respect in recent years.
IDOPATHIC PULMONARY FIBROSIS 
Idiopathic pulmonary fibrosis (IPF) is archetypal example of «lung fibrosis». It is 
the most frequent of all “fibroses”. 
IPF is defined as a specific form of chronic, progressive fibrosing interstitial pne-
umonia of unknown cause, occurring primarily in older adults, limited to the lungs, 
and associated with the histopathologic and/or radiologic pattern of usual intersti-
tial pneumonia (UIP) [10].
The diagnosis of IPF requires: a. Exclusion of other known causes of intersti-
tial lung disease (ILD) (e.g., domestic and occupational environmental exposures, 
connective tissue disease, and drug toxicity). b. The presence of a UIP pattern on 
high-resolution computed tomography (HRCT) in patients not subjected to surgical 
lung biopsy. c. Specific combinations of HRCT and surgical lung biopsy pattern in 
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patients subjected to surgical lung biopsy. The major and minor criteria proposed in 
the 2000 ATS/ERS Consensus Statement have been eliminated.
The prevalence of IPF in Europe is 2-23/100.000, Croatia 8/100.00, and in patients 
above 75 years 177/100.000. The mean length of survival after diagnosis is 3.2–5 years.
Although the disease is idiopathic, many causes or facilitating circumstan-
ces are under investigation. Exposure to an inciting agent (smoke, environmental 
pollutants, environmental dust, viral infections, gastroesophageal reflux disease, 
chronic aspiration), genetic mutations (surfactant protein C, 
 
gene encoding mucin 
5B (MUC5B), mutant telomerase known to be associated with familial idiopathic 
pulmonary fibrosis and telomere shortening which also occurs with aging and can 
also be acquired are in the focus of extensive research. This telomere shortening co-
uld promote the loss of alveolar epithelial cells, resulting in aberrant epithelial cell 
repair, and therefore should be considered as another potential contributor to the 
pathogenesis of idiopathic pulmonary fibrosis. Today the aging lung is in the focus 
of several investigations, not only regarding the pathogenesis of IPF, but also lung 
cancer and COPD [11]. 
Clinical presentation most often consists of slowly progressive breathlessness, ti-
ghtness of the chest and dry cough, which does not respond to antitussive agents. 
The symptoms are usually present for more than 6 months before presentation. 
Physical examination reveals bilateral, bibasilar, end-inspiratory fine crackles on 
auscultation (“Velcro®-like” crackles) and digital clubbing .
The diagnostic approach includes performance of radiological imaging techniqu-
es, the plain radiograph of the chest and particularly the high resolution computed 
tomography (HRCT), assessment of pulmonary function and laboratory tests, and 
open lung biopsy in those who do not fulfill the diagnostic criteria. 
Pulmonary function tests typically reveal restrictive ventilatory changes (reduced 
vital capacity [VC], and total lung capacity [TLC]) at some point in the course of the 
disease. The DLco is reduced and may precede the reduction of lung volumes. The 
respiratory arterial blood gases may be normal, or they may reveal mild hypoxemia. 
With cardiopulmonary exercise testing early abnormalities of gas exchange could 
be detected. Pulmonary hypertension rarely occurs at rest, but it is common during 
exercise.
The plain radiograph is the screening test to detect the presence of IPF, although 
it may be normal in about 10% of the patients. HRCT technique has changed the dia-
gnostic procedure in these patients as it allows earlier diagnosis and helps to narrow 
the differential diagnosis. The characteristic HRCT in IPF is the summoned feature 
of different patterns that together make the usual interstitial pneumonia (UIP) ima-
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ge ; the honeycombing, reticulation, traction bronchiectasis, architectural distortion 
and volume loss with no other specific patterns (granuloma, ground-glass, cysts, 
etc.), (Figure 1), which are inconsistent with UIP pattern [12].
Transbronchial lung biopsy is not helpful in making the diagnosis of IPF, but it 
can help to exclude some other entities that are considered in differential diagnosis. 
Open lung biopsy, or video assisted thoracoscopic (VAT) lung biopsy are perfor-
med in the minority of patients. The usual interstitial pneumonia (UIP) is the patho-
logical abnormality essential to the diagnosis of IPF; it refers to a morphologic entity 
defined by a combination of [1] patchy interstitial fibrosis with alternating areas 
of normal lung, [2] temporal heterogeneity of fibrosis characterized by scattered fi-
broblastic foci in the background of dense acellular collagen, and [3] architectural 
alteration due to chronic scarring or honeycomb change.
It is evident that some therapies are effective in the treatment of IPF. Pirfenidone 
(Esbrie) [13] and Nintedanib (Ofev) [14] show statistically significant improvement 
in clinical trials, patients taking either drug experienced significantly reduced dec-
lines in forced vital capacity compared with patients who received placebo [15]. 
Future trials are therefore unlikely to use placebo as a control group for ethical re-
asons. Future clinical assessment will probably include add-on trials in which a new 
drug is combined with an intervention with established efficacy; this development is 
in turn likely to herald the use of combination regimens in clinical practice [16]. 
The combination of inhalation NAC and pirefenidon showed that the progressi-
on-free survival PFS) in IPF was longer in the NAC plus pirfenidone group than in 
the pifenidone group [17].
GER medications due to high prevalence of gastroesophageal reflux (GER) 
showed that the use was associated with a longer survival time, additionally, pati-
ents taking GER medications had a lower fibrosis score on HRCT. 
Other recommendations are to quit smoking, oxygen therapy to maintain a sa-
turation of at least 90% at rest, with sleep, and with exertion, and vaccination against 
influenza and pneumococcal infection should be encouraged in all patients with 
idiopathic pulmonary fibrosis.
If all the earlier mentioned interventions fail, the patient deteriorates, and if the 
patient accomplishes the indications for lung transplantation he will be referred to 
the procedure.
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Sažetak
Difuzne bolesti plućnog parenhima 
Difuzne bolesti plućnog parenhima su grupa bolesti kojima je zajednička osobina da di-
fuzno zahvaćaju plućni parenhim. Plućni se parenhim sastoji od svih struktura koje se prostiru 
distalno od terminalnih bronhiola. Ove su bolesti brojne, pa tako čak oko 150 različitih entiteta 
zadovoljava kriterije uključivanja u ovu skupinu bolesti. Dijagnoza većine ovih bolesti postavlja 
se prema zajedničkom dijagnostičkom algoritmu, ali su etiologija, prognoza i terapija vrlo različi-
te. Transplantacija pluća krajnja je terapijska opcija za neke od ovih bolesti, a najčešće se zahvat 
se vrši u bolesnika s idiopatskom plućnom fibrozom. 
Ključne riječi: difuzne bolesti plućnog parenhima; transplantacija pluća; idiopatska plućna 
fibroza.
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